197TiP First-in-human (FIH) phase I/II study of ubamatamab, a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer (OC). (December 2022) - Moore, K.N.; Bouberhan, S.; Hamilton, E.; Liu, J.; O'Cearbhaill, R.E.; O'Malley, D.; Papadimitriou, K.; Schröder, D.; Van Nieuwenhuysen, E.; Yoo, S-Y.; Peterman, M.; Goncalves, P.; et al.